<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255970</url>
  </required_header>
  <id_info>
    <org_study_id>RegenF052005</org_study_id>
    <nct_id>NCT00255970</nct_id>
  </id_info>
  <brief_title>Regenafil Versus Demineralized Freeze Dried Bone Allograft (DFDBA) for Periodontal Defects</brief_title>
  <official_title>Regenerative Therapy for Vertical Defects Comparing Demineralized Freeze Dried Bone Allograft (DFDBA) and Regenafil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RTI Surgical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RTI Surgical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study was to determine whether treatment with the bone grafting
      material Regenafil was as effective as the standard treatment using demineralized freeze
      dried bone allograft (DFDBA). Regenafil is demineralized freeze dried bone in a special gel
      form.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the regenerative effects of a demineralized freeze dried bone allograft (DFDBA)
      particulate in a biologic thermoplastic carrier (Regenafil) to the standard of care. To
      compare the regenerative effects of a demineralized freeze dried bone allograft (DFDBA)
      particulate in the treatment of intraosseous vertical defects following six months of
      healing. This was accomplished by evaluating clinical parameters including probing depth,
      attachment level and bleeding upon probing, using attachment level as the primary outcome
      variable.

      Treatment of the vertical osseous defect is a challenging problem in periodontics. There are
      many treatment options including:

        1. open flap debridement;

        2. osseous graft alone;

        3. membrane alone;

        4. or membrane plus an osseous graft.

      Choice of treatment may depend on the defect depth and configuration. A shallow, narrow 3
      wall defect may respond well to open flap debridement while a deep 2 wall defect may need
      regenerative therapy such as an osseous graft, a membrane or combined membrane and graft
      treatment. Studies of vertical defect therapy with defects about 4 mm or greater show that
      similar percent defect fill results are obtained with regenerative therapies. Open flap
      debridement produces substantially less percent defect fill.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Probing Depth</measure>
    <time_frame>baseline and then at 6 months</time_frame>
    <description>This is the distance, measured in millimeters (mm) from the gingival margin to the maximal penetration of the probe tip. The measures were made at baseline and then at 6 months after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Attachment Level</measure>
    <time_frame>6 months</time_frame>
    <description>The amount of space between attached periodontal tissues and a fixed point, usually the cementoenamel junction. A measurement used to assess the stability of attachment as part of a periodontal maintenance program.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recession</measure>
    <time_frame>6 months</time_frame>
    <description>CEJ to gingival margin (GM). GM coronal to the CEJ were scored as a negative number.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gingival Index</measure>
    <time_frame>6 months</time_frame>
    <description>Scores:
0 Normal gingiva
Mild inflammation
Moderate inflammation
Severe inflammation Gingival units (buccal, lingual, mesiobuccal, distobuccal, mesiolingual, and distolingual) of each tooth were scored 0-3. Scores from the 6 areas of the tooth were added and divided by 6 to give the gingival index for the entire tooth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque Index</measure>
    <time_frame>6 months</time_frame>
    <description>0- No plaque
A film of plaque adhering to gingival margin &amp; adjacent area of tooth
Moderate accumulation of soft deposits, visible with the naked eye
Abundance of soft matter Each gingival region of the individual tooth will be scored 0-3 The scores from the 6 areas of the tooth are averaged to give the plaque index for the tooth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding on Probing</measure>
    <time_frame>6 months</time_frame>
    <description>The variable measured the presence of bleeding when the osseus defect was probed. The presence and character of gingival bleeding will be determined by gently probing to the base of the pockets.
0 - No bleeding.
1 - Bleeding when probing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobility Index</measure>
    <time_frame>6 months</time_frame>
    <description>Tooth mobility was recorded using Miller's Index:
— up to 1 mm of movement in a horizontal direction
— greater than 1 mm of movement in a horizontal direction
— excessive horizontal movement and vertical movement. Manual evaluation of mobility was carried out clinically using the handles of two instruments to move the teeth buccally and lingually and note their movement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Periodontal Diseases</condition>
  <arm_group>
    <arm_group_label>Regenafil graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regenafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DFDBA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Demineralized Freeze Dried Bone Allograft</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DFDBA</intervention_name>
    <description>Demineralized Freeze Dried Allograft bone</description>
    <arm_group_label>DFDBA</arm_group_label>
    <other_name>Demineralized Bone Matrix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Regenafil</intervention_name>
    <description>Demineralized Freeze Dried Bone in a porcine gel carrier</description>
    <arm_group_label>Regenafil graft</arm_group_label>
    <arm_group_label>DFDBA</arm_group_label>
    <other_name>Demineralized Freeze Dried Bone Allograft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent prior to their participation.

          2. Be an adult age 18 and older.

          3. Have at least a 4 mm open vertical osseous defect depth on one tooth, visible on a
             radiograph and with a probing depth ≥ 5 mm.

          4. Have osseous defects that are either wide 3-wall, or combination defects.

        Exclusion Criteria:

          1. Have debilitating systemic diseases, or diseases that affect the periodontium.

          2. Have a known allergy to any of the materials that will be used in the study:

               -  non-steroidal anti-inflammatory drugs (NSAIDs)

               -  chlorhexidine digluconate

               -  doxycycline

               -  gelatin

          3. Need prophylactic antibiotics.

          4. Have a vertical osseous defect that is related to a furcation area.

          5. Smoke more than 1 pack per day.

          6. Have endodontically treated teeth or endodontic lesions at study sites.

          7. Have 1-wall defects.

          8. Have poor oral hygiene.

          9. Have anterior fillings (Note: if a subject presents with anterior fillings, it will be
             at the discretion of the principal investigator as to whether they should be accepted
             into the study.)

         10. Be pregnant as evidenced by a positive urine pregnancy test taken at both the
             screening and baseline visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Greenwell, DMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Blanchard, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University School of Dentistry</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville School of Dentistry</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2005</study_first_submitted>
  <study_first_submitted_qc>November 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <results_first_submitted>June 9, 2009</results_first_submitted>
  <results_first_submitted_qc>July 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2011</results_first_posted>
  <last_update_submitted>August 8, 2011</last_update_submitted>
  <last_update_submitted_qc>August 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sponsor</name_title>
    <organization>Regeneration Technologies, Inc</organization>
  </responsible_party>
  <keyword>Periodontal Treatment of Intraosseous Vertical Defects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Gingival Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was done through the investigators clinics.</recruitment_details>
      <pre_assignment_details>The was no wash out or run-in events in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Regenafil</title>
          <description>Regenafil graft</description>
        </group>
        <group group_id="P2">
          <title>Demineralized Freeze Dried Bone Allograft</title>
          <description>Demineralized Freeze Dried Bone Allograft (DFDBA)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Screening Visit</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Final Visit Week 24</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Regenafil</title>
          <description>Regenafil graft</description>
        </group>
        <group group_id="B2">
          <title>Demineralized Freeze Dried Bone Allograft</title>
          <description>Demineralized Freeze Dried Bone Allograft (DFDBA)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="10.7"/>
                    <measurement group_id="B2" value="51.4" spread="14"/>
                    <measurement group_id="B3" value="51.6" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Probing Depth</title>
        <description>This is the distance, measured in millimeters (mm) from the gingival margin to the maximal penetration of the probe tip. The measures were made at baseline and then at 6 months after treatment.</description>
        <time_frame>baseline and then at 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regenafil</title>
            <description>Regenafil graft</description>
          </group>
          <group group_id="O2">
            <title>Demineralized Freeze Dried Bone Allograft</title>
            <description>Demineralized Freeze Dried Bone Allograft (DFDBA)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Probing Depth</title>
          <description>This is the distance, measured in millimeters (mm) from the gingival margin to the maximal penetration of the probe tip. The measures were made at baseline and then at 6 months after treatment.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.1"/>
                    <measurement group_id="O2" value="2.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study had been designed as a superiority study. The null hypothesis had been that there would be no significant difference in probing depth between groups at the time points measured.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;.05</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A power analysis, prior to data collection, determined that a minimum of 18 in each arm would be needed for this study.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>The power analysis had been computed for a threshold of 0.05 with a power of 0.8.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Attachment Level</title>
        <description>The amount of space between attached periodontal tissues and a fixed point, usually the cementoenamel junction. A measurement used to assess the stability of attachment as part of a periodontal maintenance program.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regenafil</title>
            <description>Regenafil graft</description>
          </group>
          <group group_id="O2">
            <title>Demineralized Freeze Dried Bone Allograft</title>
            <description>Demineralized Freeze Dried Bone Allograft (DFDBA)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Attachment Level</title>
          <description>The amount of space between attached periodontal tissues and a fixed point, usually the cementoenamel junction. A measurement used to assess the stability of attachment as part of a periodontal maintenance program.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="2.0"/>
                    <measurement group_id="O2" value="6.3" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study had been designed as a superiority study. The a priori power analysis had been designed with an effect size based on historical data. Thus, a minimal sample size of 34 patients would be necessary to determine if there was a true difference between groups, α =.05, power= 0.8. This number was then rounded to 40 patients, 20/ group (DFDBA and Regenafil).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recession</title>
        <description>CEJ to gingival margin (GM). GM coronal to the CEJ were scored as a negative number.</description>
        <time_frame>6 months</time_frame>
        <population>The number of participants to be analyzed was based on a power analysis, using a threshold of 0.05 with a power of 0.8. The power analysis indicated 18 participants were needed in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Regenafil</title>
            <description>Regenafil graft</description>
          </group>
          <group group_id="O2">
            <title>Demineralized Freeze Dried Bone Allograft</title>
            <description>Demineralized Freeze Dried Bone Allograft (DFDBA)</description>
          </group>
        </group_list>
        <measure>
          <title>Recession</title>
          <description>CEJ to gingival margin (GM). GM coronal to the CEJ were scored as a negative number.</description>
          <population>The number of participants to be analyzed was based on a power analysis, using a threshold of 0.05 with a power of 0.8. The power analysis indicated 18 participants were needed in each arm</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.1"/>
                    <measurement group_id="O2" value="0.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change in recession, measured in mm, had been designed as a superiority study. The a priori power analysis had been designed with an effect size based on historical data. Thus, a minimal sample size of 34 patients would be necessary to determine if there was a true difference between groups, α =.05, power= 0.8. This number was then rounded to 40 patients, 20/ group (DFDBA and Regenafil).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gingival Index</title>
        <description>Scores:
0 Normal gingiva
Mild inflammation
Moderate inflammation
Severe inflammation Gingival units (buccal, lingual, mesiobuccal, distobuccal, mesiolingual, and distolingual) of each tooth were scored 0-3. Scores from the 6 areas of the tooth were added and divided by 6 to give the gingival index for the entire tooth.</description>
        <time_frame>6 months</time_frame>
        <population>As stated in the protocol, the power analysis (threshold=0.05, power&gt;0.8) noted 18 subjects would be needed per group.</population>
        <group_list>
          <group group_id="O1">
            <title>Regenafil</title>
            <description>Regenafil graft</description>
          </group>
          <group group_id="O2">
            <title>Demineralized Freeze Dried Bone Allograft</title>
            <description>Demineralized Freeze Dried Bone Allograft (DFDBA)</description>
          </group>
        </group_list>
        <measure>
          <title>Gingival Index</title>
          <description>Scores:
0 Normal gingiva
Mild inflammation
Moderate inflammation
Severe inflammation Gingival units (buccal, lingual, mesiobuccal, distobuccal, mesiolingual, and distolingual) of each tooth were scored 0-3. Scores from the 6 areas of the tooth were added and divided by 6 to give the gingival index for the entire tooth.</description>
          <population>As stated in the protocol, the power analysis (threshold=0.05, power&gt;0.8) noted 18 subjects would be needed per group.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.8"/>
                    <measurement group_id="O2" value="0.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each gingival unit (buccal, lingual, mesiobuccal, distobuccal, mesiolingual, and distolingual) of the individual tooth will be given a score from 0-3, called the gingival index for the area. The scores from the 6 areas of the tooth are added and divided by 6 to give the gingival index for the tooth.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plaque Index</title>
        <description>0- No plaque
A film of plaque adhering to gingival margin &amp; adjacent area of tooth
Moderate accumulation of soft deposits, visible with the naked eye
Abundance of soft matter Each gingival region of the individual tooth will be scored 0-3 The scores from the 6 areas of the tooth are averaged to give the plaque index for the tooth.</description>
        <time_frame>6 months</time_frame>
        <population>The number of participants to be analyzed was based on a power analysis, using a threshold of 0.05 with a power of 0.8. The power analysis indicated 18 participants were needed in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Regenafil</title>
            <description>Regenafil graft</description>
          </group>
          <group group_id="O2">
            <title>Demineralized Freeze Dried Bone Allograft</title>
            <description>Demineralized Freeze Dried Bone Allograft (DFDBA)</description>
          </group>
        </group_list>
        <measure>
          <title>Plaque Index</title>
          <description>0- No plaque
A film of plaque adhering to gingival margin &amp; adjacent area of tooth
Moderate accumulation of soft deposits, visible with the naked eye
Abundance of soft matter Each gingival region of the individual tooth will be scored 0-3 The scores from the 6 areas of the tooth are averaged to give the plaque index for the tooth.</description>
          <population>The number of participants to be analyzed was based on a power analysis, using a threshold of 0.05 with a power of 0.8. The power analysis indicated 18 participants were needed in each arm</population>
          <units>Categorical index score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.5"/>
                    <measurement group_id="O2" value="0.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study had been designed as a superiority study. The a priori power analysis had been designed with an effect size based on historical data. Thus, a minimal sample size of 34 patients would be necessary to determine if there was a true difference between groups, α =.05, power= 0.8. This number was then rounded to 40 patients, 20/ group (DFDBA and Regenafil).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding on Probing</title>
        <description>The variable measured the presence of bleeding when the osseus defect was probed. The presence and character of gingival bleeding will be determined by gently probing to the base of the pockets.
0 - No bleeding.
1 - Bleeding when probing.</description>
        <time_frame>6 months</time_frame>
        <population>The a priori power analysis had been designed with an effect size based on historical data. Thus, a minimal sample size of 34 patients would be necessary to determine if there was a true difference between groups, α =.05, power= 0.8. This number was then rounded to 40 patients, 20/ group (DFDBA and Regenafil).</population>
        <group_list>
          <group group_id="O1">
            <title>Regenafil</title>
            <description>Regenafil graft</description>
          </group>
          <group group_id="O2">
            <title>Demineralized Freeze Dried Bone Allograft</title>
            <description>Demineralized Freeze Dried Bone Allograft (DFDBA)</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding on Probing</title>
          <description>The variable measured the presence of bleeding when the osseus defect was probed. The presence and character of gingival bleeding will be determined by gently probing to the base of the pockets.
0 - No bleeding.
1 - Bleeding when probing.</description>
          <population>The a priori power analysis had been designed with an effect size based on historical data. Thus, a minimal sample size of 34 patients would be necessary to determine if there was a true difference between groups, α =.05, power= 0.8. This number was then rounded to 40 patients, 20/ group (DFDBA and Regenafil).</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.3"/>
                    <measurement group_id="O2" value="0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mobility Index</title>
        <description>Tooth mobility was recorded using Miller's Index:
— up to 1 mm of movement in a horizontal direction
— greater than 1 mm of movement in a horizontal direction
— excessive horizontal movement and vertical movement. Manual evaluation of mobility was carried out clinically using the handles of two instruments to move the teeth buccally and lingually and note their movement.</description>
        <time_frame>6 months</time_frame>
        <population>A power analysis, prior to data collection, determined that a minimum of 18 in each arm would be needed for this study. The power analysis had been computed for a threshold of 0.05 with a power of 0.8.</population>
        <group_list>
          <group group_id="O1">
            <title>Regenafil</title>
            <description>Regenafil graft</description>
          </group>
          <group group_id="O2">
            <title>Demineralized Freeze Dried Bone Allograft</title>
            <description>Demineralized Freeze Dried Bone Allograft (DFDBA)</description>
          </group>
        </group_list>
        <measure>
          <title>Mobility Index</title>
          <description>Tooth mobility was recorded using Miller's Index:
— up to 1 mm of movement in a horizontal direction
— greater than 1 mm of movement in a horizontal direction
— excessive horizontal movement and vertical movement. Manual evaluation of mobility was carried out clinically using the handles of two instruments to move the teeth buccally and lingually and note their movement.</description>
          <population>A power analysis, prior to data collection, determined that a minimum of 18 in each arm would be needed for this study. The power analysis had been computed for a threshold of 0.05 with a power of 0.8.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.5"/>
                    <measurement group_id="O2" value="0.6" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Regenafil</title>
          <description>Regenafil graft</description>
        </group>
        <group group_id="E2">
          <title>Demineralized Freeze Dried Bone Allograft</title>
          <description>Demineralized Freeze Dried Bone Allograft (DFDBA)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Projects, Director</name_or_title>
      <organization>RTI Biologics</organization>
      <phone>386-418-8888</phone>
      <email>rparkhurst@rtix.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

